Table II.
Immunohistochemical characteristics of invasive breast carcinoma prior and following therapy.
| Marker | Pre therapy, n (%) | Post therapy, n (%) |
|---|---|---|
| Claudin-1 | ||
| High | 25 (40) | 34 (55) |
| Low | 37 (60) | 28 (45) |
| Claudin-3 | ||
| High | 59 (95) | 51 (82) |
| Low | 3 (5) | 11 (18) |
| Claudin-4 | ||
| High | 61 (98) | 58 (94) |
| Low | 1 (2) | 4 (6) |
| E-cadherin | ||
| Normal | 47 (76) | 44 (71) |
| Aberrant | 15 (24) | 18 (29) |
| N-cadherin | ||
| Negative | 47 (76) | 48 (77) |
| Positive | 15 (24) | 14 (23) |
| ER | ||
| Positive | 45 (73) | 48 (77) |
| Negative | 17 (27) | 14 (23) |
| PR | ||
| Positive | 39 (63) | 35 (56) |
| Negative | 23 (37) | 27 (44) |
| HER2 | ||
| Positive | 8 (13) | 12 (19) |
| Negative | 54 (87) | 50 (81) |
| Ki-67 | ||
| High | 43 (70) | 25 (40) |
| Low | 19 (30) | 37 (60) |
| Triple-negative breast cancer | 12 (19) | 10 (16) |
The level of expression is categorized high-low, positive-negative or normal-aberrant according to the expected impact on tumour biology and/or response to therapy. ER, oestrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; Ki-67, marker of proliferation Ki-67.